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Development of clinical pathway for mild cognitive impairment and dementia to 
quantify cost of age-related cognitive disorders in Malaysia 
ABSTRACT 
As the Malaysian population ages, the burden of age-related cognitive disorders such as 
dementia and Alzheimer’s disease will increase concomitantly. This is one of the sub-study 
under a research project titled by quantify the cost of age-related cognitive impairment in 
Malaysia, which was undertaken to develop a clinical pathway for Mild Cognitive 
Impairment (MCI) and Dementia. The clinical pathway (CP) will be used to support the 
costing studies of MCI and Dementia. An expert group discussion (EGD) was conducted 
among selected experts from six (6) government hospitals from different states of Malaysia, 
Ministry of Health, and United Nations University, International Institute for Global Health, 
UKM and UPM. The expert group includes psychiatrist specialists and public health 
medicine specialists. A total of 15 participants took part in the EGD. The group was 
presented with the different approach in managing MCI and Dementia. Finally, the group 
came to the consensus agreement on the most appropriate and efficient ways of managing the 
two conditions. In the EGD, an operational definition for MCI and Dementia was agreed 
upon and a pathway was developed for the usual practice in the Malaysian health system. A 
typical case used, as a reference is a 60-year-old patient referred to a memory clinic with 
complaint of “forgetfulness”. After three outpatient visits in the clinic, the diagnosis of MCI 
and Dementia could be clinically established. The clinical pathways covered all active 
clinical and non-clinical management of the patient over a period of one year. The experts 
identified the additional resources required to manage these patients for the whole spectrum 
of lifetime based on the expected life expectancy. The Clinical pathway (CP) for MCI and 
Dementia was successfully developed in EGD with strong support from practitioners in the 
health system. The findings will help the researchers to identify all-important clinical 
activities and interventions that will be included in the costing study. 
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